Cargando…
SAT466 Inactive Thyroid Eye Disease Patient Journey
Disclosure: K. Cockerham: Consulting Fee; Self; Horizon Therapeutics plc, Viridian. T.J. Smith: Consulting Fee; Self; Horizon Therapeutics plc, Viridian, Lundbeck. Other; Self; US patents covering the use of IGF-1 receptor inhibitors in TED which are held by UCLA and the Lundquist Institute. E. Conr...
Autores principales: | Cockerham, Kimberly, Smith, Terry J, Conrad, Elizabeth, Holt, Robert J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553666/ http://dx.doi.org/10.1210/jendso/bvad114.1940 |
Ejemplares similares
-
SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023) -
SAT-466 Hashimoto’s Glomerulonephritis: A Reality or Just a Coincidence?
por: Gomez Noronha, Andres Alberto, et al.
Publicado: (2020) -
RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022) -
SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020) -
SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)